Gene expression signatures and outcome prediction in mature B-cell malignancies

Current Treatment Options in Oncology

Volumn 7, Issue 4, 2006, Pages 261-269

  Dave, Sandeep S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CD2 ANTIGEN; CD3 ANTIGEN; CD30 ANTIGEN; CD64 ANTIGEN; CD7 ANTIGEN; CD8 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; CYCLOPHOSPHAMIDE; DOXORUBICIN; HERMES ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MYC PROTEIN; OSTEONECTIN; PHOSPHODIESTERASE IV; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN KINASE C BETA; RITUXIMAB; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TOLL LIKE RECEPTOR 5; TUBULIN; UNINDEXED DRUG; VINCRISTINE;

B CELL LYMPHOMA; B LYMPHOCYTE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; DIAGNOSTIC VALUE; DISEASE COURSE; DNA MICROARRAY; FOLLICULAR LYMPHOMA; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GERMINAL CENTER; HUMAN; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PATIENT SELECTION; PREDICTION; PROGNOSIS; RELIABILITY; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR IMMUNITY;

FORECASTING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOMA, B-CELL; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS;

EID: 33745888061     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-006-0035-4     Document Type: Review

References (30)

1. Schena M, Shalon D, Davis RW, Brown PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995, 270:467-470.
2. Shaffer AL, Rosenwald A, Hurt EM, et al.: Signatures of the immune response. Immunity 2001, 15:375-385.
3. Monti S, Savage KJ, Kutok JL, et al.: Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005, 105:1851-1861.
4. Kobayashi T, Kim S, Zhang W, et al.: Gene expression profiling of de novo CD 5-positive diffuse large B-cell lymphoma. Rinsho Ketsueki 2003, 44:144-148.
5. Alizadeh AA, Eisen MB, Davis RE, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
6. Wright G, Tan B, Rosenwald A, et al.: A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003, 100:9991-9996.
7. Rosenwald A, Wright G, Chan WC, et al.: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937-1947.
8. Shipp M: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993, 329:987-994.
9. Lossos IS, Czerwinski DK, Alizadeh AA, et al.: Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004, 350:1828-1837.
10. Shipp MA, Ross KN, Tamayo P, et al.: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002, 8:68-74.
11. Basso K, Margolin AA, Stolovitzky G, et al.: Reverse engineering of regulatory networks in human B cells. Nat Genet 2005, 37:382-390.
12. Rimsza LM, Roberts RA, Campo E, et al.: Loss of major histocompatibility class II expression in non-immune privileged site diffuse large B cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood 2005, 107:1101-1107.
13. Mounier N, Briere J, Gisselbrecht C, et al.: Rituximab plus CHOP (R-CHOP) overcomes bcl-2 - associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003, 101:4279-4284.
14. Winter JN, Weller EA, Horning SJ, et al.: Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006, In press.
15. Horning SJ: Follicular lymphoma: have we made any progress? Ann Oncol 2000, 11(Suppl 1):23-27.
16. Shaffer AL, Rosenwald A, Staudt LM: Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2002, 2:920-932.
17. Lossos IS, Levy R: Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions. Semin Cancer Biol 2003, 13:191-202.
18. Dave SS, Wright C, Tan B, et al.: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004, 351:2159-2169.
19. Farinha P, Masoudi H, Skinnider BF, et al.: Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005, 106:2169-2174.
20. Rosenwald A, Wright G, Wiestner A, et al.: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3:185-197.
21. Velders GA, Kluin-Nelemans JC, De Boer CJ, et al.: Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol 1996, 14:1269-1274.
22. Addis BJ, Isaacson PG: Large cell lymphoma of the mediastinum: a B-cell tumour of probable thymic origin. Histopathology 1986, 10:379-390.
23. Savage KJ, Monti S, Kutok JL, et al.: The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003, 102:3871-3879.
24. Rosenwald A, Wright G, Leroy K, et al.: Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003, 198:851-862.
25. Rosenwald A, Alizadeh AA, Widhopf G, et al.: Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001, 194:1639-1648.
26. Wiestner A, Rosenwald A, Barry TS, et al.: ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003, 101:4944-4951.
27. Crespo M, Bosch F, Villamor N, et al.: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003, 348:1764-1775.
28. Rassenti LZ, Huynh L, Toy TL, et al.: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004, 351:893-901.
29. Hoefnagel JJ, Dijkman R, Basso K, et al.: Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 2005, 105:3671-3678.
30. Ruiz-Ballesteros E, Mollejo M, Rodriguez A, et al.: Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood 2005, 106:1831-1838.